Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants

被引:36
作者
Exner, Thomas [1 ]
Ahuja, Monica [1 ]
Ellwood, Lisa [1 ]
机构
[1] Haematex Res, Unit 9,17 King Rd, Sydney, NSW 2077, Australia
关键词
activated charcoal; anticoagulants; argatroban; APTT; DOAC Stop (TM); DOACs; (dabigatran; apixaban; rivaroxaban; edoxaban); coagulation inhibitors; hirudin; protamine; POLYMYXIN-B; INHIBITION;
D O I
10.1515/cclm-2018-0967
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The aim of the study was to investigate the specificity of an activated charcoal-based product (DOAC StopTM) initially intended for the specific extraction of direct oral anticoagulants (DOACs) from test plasmas on a range of other anticoagulants. Methods: Test plasmas were prepared by adding various anticoagulants to pooled normal plasma at concentrations prolonging an activated partial thromboplastin time (APTT) test by a factor of 1.5-3. These plasmas were treated with DOAC Stop (TM) for 5 and 20 min. Then APTTs were repeated and residual anticoagulant concentrations estimated from dose-response curves. Results: The activated charcoal (AC)-based product was found to extract DOACs efficiently. It also bound the intravenous anticoagulants argatroban and lepirudin, but it had no effect on heparin, enoxaparin or danaparoid in plasma. Among other APTT-inhibiting agents that might be present in test plasmas from patients, it extracted protamine, aprotinin and polymyxin. It had no effect on annexin V, thrombomodulin, a typical lupus anticoagulant, a factor VIII antibody, activated protein C or its activator, but it did bind some cationic inhibitors of the APTT with molecular weight below approximately 30 kDa. Conclusions: The AC-based product extracted DOACs efficiently with no effect on heparin-type anticoagulants. It did bind argatroban and hirudin-type anticoagulants, which might occur in plasmas from some inpatients, and APTT results obtained after its use should be interpreted after due consideration of patient medications.
引用
收藏
页码:690 / 696
页数:7
相关论文
共 15 条
  • [1] [Anonymous], TH OPEN
  • [2] Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia (Reprinted from Journal of Health-System Pharmacy Residents JHPR, vol 1, issue 4, 2013)
    Bain, Jonathan
    Meyer, Andrew
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (17) : S104 - S109
  • [3] Antidotes for Novel Oral Anticoagulants Current Status and Future Potential
    Crowther, Mark
    Crowther, Mark A.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (08) : 1736 - 1745
  • [4] Simple method for removing DOACs from plasma samples
    Exner, T.
    Michalopoulos, N.
    Pearce, J.
    Xavier, R.
    Ahuja, M.
    [J]. THROMBOSIS RESEARCH, 2018, 163 : 117 - 122
  • [5] EXNER T, 1995, THROMB HAEMOSTASIS, V74, P338
  • [6] The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays
    Jacquemin, M.
    Toelen, J.
    Feyen, L.
    Schoeters, J.
    Van Horenbeeck, I.
    Vanlinthout, I.
    Debasse, M.
    Vanassche, T.
    Peerlinck, K.
    Verhamme, P.
    [J]. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (04) : 442 - 447
  • [7] The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph
    Khan, Nouman U.
    Wayne, Charlotte K.
    Barker, Julian
    Strang, Timothy
    [J]. EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2010, 27 (07) : 624 - 627
  • [8] Colistin and polymyxin B in critical care
    Michalopoulos, Argyris
    Falagas, Matthew E.
    [J]. CRITICAL CARE CLINICS, 2008, 24 (02) : 377 - +
  • [9] INHIBITION OF HAGEMAN FACTOR ACTIVATION
    NOSSEL, HL
    RUBIN, H
    DRILLINGS, M
    HSIEH, R
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1968, 47 (05) : 1172 - +
  • [10] Effect of Activated Charcoal on Rivaroxaban Complex Absorption
    Ollier, Edouard
    Hodin, Sophie
    Lanoiselee, Julien
    Escal, Jean
    Accassat, Sandrine
    De Magalhaes, Elodie
    Basset, Thierry
    Bertoletti, Laurent
    Mismetti, Patrick
    Delavenne, Xavier
    [J]. CLINICAL PHARMACOKINETICS, 2017, 56 (07) : 793 - 801